Ejaculatory Function Disorders in Male Patients

Ejaculatory function disorders encompass a spectrum of conditions affecting the timing, control and satisfaction of male sexual response. The most common is premature ejaculation, defined by consistently short latency and lack of voluntary control leading to distress for patient and partner. By contrast, delayed ejaculation is characterised by prolonged latency or inability to achieve ejaculation despite adequate sexual stimulation. Less frequent subtypes include anejaculation, where ejaculation fails to occur, and retrograde ejaculation, in which semen flows into the bladder. These conditions can arise from psychological factors, neurobiological alterations, endocrinopathies, pharmacological interventions or systemic diseases. Epidemiological studies indicate a global prevalence for premature ejaculation of around 20–30%, with significant impacts on quality of life and intimate relationships. Diagnostic assessment relies on patient history, validated questionnaires and measurement of intravaginal ejaculatory latency time. Management strategies range from behavioural techniques to topical agents, systemic pharmacotherapy with selective serotonin reuptake inhibitors and novel neuromodulatory approaches. Advances in neuroimaging and molecular pharmacology have begun to elucidate the central and peripheral pathways governing ejaculatory control, creating opportunities for targeted therapies and personalised care.

Research from Nature Portfolio

Large-scale population analysis within a European cohort has refined estimates of ejaculatory dysfunction, revealing that premature ejaculation affects approximately one in five adult men and is associated with considerable psychosocial burden. Despite high prevalence, treatment-seeking behaviour remains low, underscoring the need for public health campaigns and clinician education. Functional neuroimaging studies have further delineated the neural circuits implicated in lifelong premature ejaculation. Combined task-based and resting-state functional magnetic resonance imaging has identified reduced activity in prefrontal and insular regions alongside altered connectivity within limbic-motor networks. These findings support a neurobiological basis for ejaculatory control and offer potential imaging biomarkers to guide future interventions.

Ejaculatory Function Disorders in Male Patients publication trend

The graph below shows the total number of articles in ejaculatory function disorders in male patients across all publications each year (not limited to Nature Index journals).

Technical terms

Premature ejaculation (PE): Ejaculatory disorder characterised by short latency, lack of control and distress.

Intravaginal ejaculatory latency time (IELT): Duration from vaginal penetration to ejaculation, used as an objective measure in research and diagnosis.

Selective serotonin reuptake inhibitor (SSRI): Class of antidepressant drugs that increase serotonin levels, used off-label to delay ejaculation.

Functional connectivity: Statistical interrelationship between activity in distinct brain regions, often assessed by functional MRI.

5-HT1A receptor antagonist: Compound that blocks the inhibitory serotonin receptor subtype, investigated in combination with SSRIs for ejaculatory control.

References

1. Population-level prevalence, effect on quality of life, and treatment behavior for erectile dysfunction and premature ejaculation in Poland. Scientific Reports (2023).
2. Comparison of Current International Guidelines on Premature Ejaculation: 2024 Update. Diagnostics (2024).
3. A new approach to ‘on-demand’ treatment of lifelong premature ejaculation by treatment with a combination of a 5-HT1A receptor antagonist and SSRI in rats. Frontiers in Neuroscience (2023).
4. Functional insights into aberrant brain responses and integration in patients with lifelong premature ejaculation. Scientific Reports (2017).
5. Premature Ejaculation: Aetiology and Treatment Strategies. Medical Sciences (2019).